Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations

Summary

This study is designed to assess the effect of once-daily QVA149 on COPD exacerbations in patients with severe to very severe COPD.

Timeline

Start

2010-04

Primary completion

2012-07

Completion

2012-07

Outcome

Met primary endpoint

paper QVA149 significantly reduced the rate of moderate to severe exacerbations versus glycopyrronium by 12% PMID 24429126 ↗

paper rate ratio 0·88, 95% CI 0·77-0·99, p=0·038 PMID 24429126 ↗

Publications

• Wedzicha JA, Decramer M, Ficker JH, Niewoehner DE, Sandstrom T, Taylor AF, D'Andrea P, Arrasate C, Chen H, Banerji D. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med. 2013 May;1(3):199-209. doi: 10.1016/S2213-2600(13)70052-3. Epub 2013 Apr 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Glycopyrronium	Unknown	50 ug	Inhaled
Subject	Indacaterol	Other / unclassified	110 ug	Inhaled
Comparator	Tiotropium	Other / unclassified	18 ug	Inhaled
Background	Salbutamol	Unknown	—	—

Indications